Physician profile
Danette Null
NPI 1336129444
$363.82
in general payments reported to CMS, 2019-2025
14 companies · $48.75 in 2025
The $48.75 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $56.48 · 2020: $25.33 · 2021: $28.09 · 2023: $95.49 · 2024: $110 · 2025: $48.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $254.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $253.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $64.28 | 2023-2024 | Veozah |
| Janssen Pharmaceuticals, INC | $63.54 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $30.15 | 2021-2023 | Camzyos |
| Insulet Corporation | $24.86 | 2025 | Omnipod |
| Organon LLC | $23.89 | 2025 | Nexplanon |
| Abbott Laboratories | $22.40 | 2023 | Freestyle Libre 3 |
| Haemonetics Corporation | $21.93 | 2023 | |
| Sobi, INC | $21.19 | 2019 | |
| Novo Nordisk INC | $20.32 | 2024 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $15.58 | 2023 | Farxiga |
| Exact Sciences Corporation | $15.51 | 2024 | Cologuard Collection Kit |
| Supernus Pharmaceuticals, INC. | $15.31 | 2024 | Qelbree |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $13.77 | 2024 | |
| Pfizer INC. | $11.09 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Danette Null listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.